ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 1, 2013, Pages 64-79

  Zamek Gliszczynski, M J ^a   Lee, C A ^b   Poirier, A ^c   Bentz, J ^d   Chu, X ^e   Ellens, H ^f   Ishikawa, T ^g   Jamei, M ^h   Kalvass, J C ⁱ   Nagar, S ^j   Pang, K S ^k   Korzekwa, K ^j   Swaan, P W ^l   Taub, M E ^m   Zhao, P ⁿ   Galetin, A ^o  

^a ELI LILLY AND COMPANY   (United States)

^b QPS DMPK Hepatic Biosciences   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d DREXEL UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f GLAXOSMITHKLINE   (United States)

^g RIKEN YOKOHAMA INSTITUTE   (Japan)

^h CERTARA UK LIMITED   (United Kingdom)

ⁱ ABBOTT LABORATORIES   (United States)

^j TEMPLE UNIVERSITY   (United States)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY OF MARYLAND   (United States)

^m BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁿ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^o UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; BILE SALT EXPORT PUMP PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DIGOXIN; FEXOFENADINE; GLYCOPROTEIN P INHIBITOR; IBUPROFEN; INDOMETACIN; LOSARTAN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAPSAGATRAN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 2; PRAVASTATIN; PROTEIN ABCB11; PROTEIN SLC22A6; PROTEIN SLC47A1; PROTEIN SLC47A2; RAMATROBAN; REPAGLINIDE; SULFAFURAZOLE; TELMISARTAN; TOLMETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

BILIARY EXCRETION; BRAIN; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; DIFFUSION; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; GENE INACTIVATION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; KIDNEY CLEARANCE; LIVER; MEMBRANE PERMEABILITY; MODEL; NONHUMAN; PARTITION COEFFICIENT; PASSIVE TRANSPORT; PERMEABILITY BARRIER; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STATISTICAL MODEL; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BRAIN; DRUG INTERACTIONS; GUIDELINES AS TOPIC; HUMANS; KIDNEY; LIVER; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 84879416924     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.45     Document Type: Review

References (75)

1. Giacomini, K.M. et al. Membrane transporters in drug development. Nat. Rev. Drug. Discov. 9, 215-236 (2010).
2. Zamek-Gliszczynski, M.J., Hofmaster, K.A., Tweedie, D.J., Giacomini, K.M. & Hillgren, K.M. Highlights from the International Transporter Consortium second workshop. Clin. Pharmacol. Ther. 92, 553-556 (2012).
3. Poirier, A. et al. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab. Dispos. 36, 2434-2444 (2008).
4. Noé, J., Portmann, R., Brun, M.E. & Funk, C. Substrate-dependent drug-drug interactions between gemfbrozil, fuvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 35, 1308-1314 (2007).
5. Ménochet, K., Kenworthy, K.E., Houston, J.B. & Galetin, A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J. Pharmacol. Exp. Ther. 341, 2-15 (2012).
6. Ménochet, K., Kenworthy, K.E., Houston, J.B. & Galetin, A. Use of mechanistic modeling to assess interindividual variability and interspecies diferences in active uptake in human and rat hepatocytes. Drug Metab. Dispos. 40, 1744-1756 (2012).
7. Paine, S.W., Parker, A.J., Gardiner, P., Webborn, P.J. & Riley, R.J. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab. Dispos. 36, 1365-1374 (2008).
8. Jones, H.M. et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab. Dispos. 40, 1007-1017 (2012).
9. Watanabe, T. et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab. Dispos. 38, 215-222 (2010).
10. Geng, W., Schwab, A.J., Horie, T., Goresky, C.A. & Pang, K.S. Hepatic uptake of bromosulfophthalein-glutathione in perfused Eisai hyperbilirubinemic mutant rat liver: a multiple-indicator dilution study. J. Pharmacol. Exp. Ther. 284, 480-492 (1998).
11. Troutman, M.D. & Thakker, D.R. Efux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric efect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 20, 1200-1209 (2003).
12. Kalvass, J.C. & Pollack, G.M. Kinetic considerations for the quantitative assessment of efux activity and inhibition: implications for understanding and predicting the efects of efux inhibition. Pharm. Res. 24, 265-276 (2007).
13. Shirasaka, Y., Sakane, T. & Yamashita, S. Efect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J. Pharm. Sci. 97, 553-565 (2008).
14. Tachibana, T. et al. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm. Res. 27, 442-446 (2010).
15. Sun, H. & Pang, K.S. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab. Dispos. 36, 102-123 (2008).
16. Taub, M.E. et al. Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells. Drug Metab. Dispos. 39, 2093-2102 (2011).
17. Korzekwa, K.R., Nagar, S., Tucker, J., Weiskircher, E.A., Bhoopathy, S. & Hidalgo, I.J. Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab. Dispos. 40, 865-876 (2012).
18. Bentz, J., Tran, T.T., Polli, J.W., Ayrton, A. & Ellens, H. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confuent cell monolayer cannot predict the correct Michaelis constant Km. Pharm. Res. 22, 1667-1677 (2005).
19. Lumen, A.A., Acharya, P., Polli, J.W., Ayrton, A., Ellens, H. & Bentz, J. If the KI is defned by the free energy of binding to P-glycoprotein, which kinetic parameters defne the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confuent cell monolayer? Drug Metab. Dispos. 38, 260-269 (2010).
20. Hirano, M., Maeda, K., Shitara, Y. & Sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229-1236 (2006).
21. Varma, M.V. et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol. Pharm. 8, 1303-1313 (2011).
22. Gertz, M. et al. Application of PBPK modeling in the assessment of the interaction potential of cyclosporine against hepatic and intestinal uptake and efux transporters and CYP3A4. Pharm. Res. 30, 761-780 (2013).
23. Zolnerciks, J.K., Booth-Genthe, C.L., Gupta, A., Harris, J. & Unadkat, J.D. Substrate-and species-dependent inhibition of P-glycoprotein- mediated transport: implications for predicting in vivo drug interactions. J. Pharm. Sci. 100, 3055-3061 (2011).
24. Engel, A., Oswald, S., Siegmund, W. & Keiser, M. Pharmaceutical excipients infuence the function of human uptake transporting proteins. Mol. Pharm. 9, 2577-2581 (2012).
25. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
26. Ekins, S., Polli, J.E., Swaan, P.W. & Wright, S.H. Computational modeling to accelerate the identifcation of substrates and inhibitors for transporters that afect drug disposition. Clin. Pharmacol. Ther. 92, 661-665 (2012).
27. Zamek-Gliszczynski, M.J., Bedwell, D.W., Bao, J.Q. & Higgins, J.W. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofuorescein pharmacokinetics. Drug Metab. Dispos. 40, 1825-1833 (2012).
28. Breedveld, P., Beijnen, J.H. & Schellens, J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27, 17-24 (2006).
29. Kodaira, H., Kusuhara, H., Ushiki, J., Fuse, E. & Sugiyama, Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, favopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther. 333, 788-796 (2010).
30. Zamek-Gliszczynski, M.J., Kalvass, J.C., Pollack, G.M. & Brouwer, K.L. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab. Dispos. 37, 386-390 (2009).
31. Zhao, R. et al. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efux at the blood-brain barrier. Drug Metab. Dispos. 37, 1251-1258 (2009).
32. Polli, J.W. et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fuorobenzyl) oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl] -4-quinazolinamine; GW572016). Drug Metab. Dispos. 37, 439-442 (2009).
33. DeGorter, M.K. & Kim, R.B. Use of transgenic and knockout mouse models to assess solute carrier transporter function. Clin. Pharmacol. Ther. 89, 612-616 (2011).
34. Badolo, L., Rasmussen, L.M., Hansen, H.R. & Sveigaard, C. Screening of OATP1B1/3 and OCT1 inhibitors in cryopreserved hepatocytes in suspension. Eur. J. Pharm. Sci. 40, 282-288 (2010).
35. Iusuf, D. et al. Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol. Pharm. 9, 2497-2504 (2012).
36. van de Steeg, E. et al. Complete OATP1B1 and OATP1B3 defciency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J. Clin. Invest. 122, 519-528 (2012).
37. Higgins, J.W., Bedwell, D.W. & Zamek-Gliszczynski, M.J. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no efect on tissue drug exposure and pharmacodynamics. Drug Metab. Dispos. 40, 1170-1177 (2012).
38. Woodland, J.M. et al. Metabolism and disposition of the antifolate LY231514 in mice and dogs. Drug Metab. Dispos. 25, 693-700 (1997).
39. Kivistö, K.T. et al. Disposition of oral and intravenous pravastatin in MRP2-defcient TR-rats. Drug Metab. Dispos. 33, 1593-1596 (2005).
40. Tsuda, M., Terada, T., Mizuno, T., Katsura, T., Shimakura, J. & Inui, K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol. 75, 1280-1286 (2009).
41. Williams, J.A. et al. Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32, 1201-1208 (2004).
42. Tian, X. et al. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob. Agents Chemother. 51, 3230-3234 (2007).
43. Rostami-Hodjegan, A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther. 92, 50-61 (2012).
44. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011).
45. Yang, J., Jamei, M., Yeo, K.R., Tucker, G.T. & Rostami-Hodjegan, A. Prediction of intestinal frst-pass drug metabolism. Curr. Drug Metab. 8, 676-684 (2007).
46. Gertz, M., Harrison, A., Houston, J.B. & Galetin, A. Prediction of human intestinal frst-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 38, 1147-1158 (2010).
47. Pang, K.S. & Chow, E.C. Commentary: theoretical predictions of fow efects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated fow model, and QGut model. Drug Metab. Dispos. 40, 1869-1877 (2012).
48. Umehara, K. & Camenisch, G. Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat. Pharm. Res. 29, 603-617 (2012).
49. Paine, S.W., Ménochet, K., Denton, R., McGinnity, D.F. & Riley, R.J. Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab. Dispos. 39, 1008-1013 (2011).
50. Kusuhara, H. & Sugiyama, Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab. Pharmacokinet. 24, 37-52 (2009).
51. Watanabe, T. et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab. Dispos. 39, 1031-1038 (2011).
52. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652-662 (2009).
53. Kalvass, J.C., Olson, E.R., Cassidy, M.P., Selley, D.E. & Pollack, G.M. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J. Pharmacol. Exp. Ther. 323, 346-355 (2007).
54. Agarwal, S., Arya, V. & Zhang, L. Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I(1)]/IC(50) and [I(2)]/IC(50) criteria in the P-gp decision tree. J. Clin. Pharmacol. 53, 228-233 (2013).
55. Hinton, L.K., Galetin, A. & Houston, J.B. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplifed by gemfbrozil-drug interactions. Pharm. Res. 25, 1063-1074 (2008).
56. Yoshida, K., Ohguro, I. & Ohguro, H. Black currant anthocyanins normalized abnormal levels of serum concentrations of endothelin-1 in patients with glaucoma. J. Ocul. Pharmacol. Ther. (2012); e-pub ahead of print 21 December 2012.
57. Poirier, A., Cascais, A.C., Funk, C. & Lavé, T. Prediction of pharmacokinetic profle of valsartan in human based on in vitro uptake transport data. J. Pharmacokinet. Pharmacodyn. 36, 585-611 (2009).
58. Poirier, A., Funk, C., Scherrmann, J.M. & Lavé, T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol. Pharm. 6, 1716-1733 (2009).
59. Agoram, B., Woltosz, W.S. & Bolger, M.B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (suppl. 1), S41-S67 (2001).
60. Tam, D., Tirona, R.G. & Pang, K.S. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab. Dispos. 31, 373-383 (2003).
61. Jamei, M. et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225-237 (2009).
62. Gertz, M., Houston, J.B. & Galetin, A. Physiologically based pharmacokinetic modeling of intestinal frst-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos. 39, 1633-1642 (2011).
63. Kawai, R., Mathew, D., Tanaka, C. & Rowland, M. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J. Pharmacol. Exp. Ther. 287, 457-468 (1998).
64. Burt, H.J., Neuhof, S., Lu, G., Jamei, M., Tucker, G.T. & Rostami-Hodjegan, A. Simulation of the efect of urine pH on renal drug clearance using a novel population based mechanistic kidney model (Mech KiM). Gordon Research Conference-Drug Metabolism, Holderness, NH, 8-13 July 2012.
65. Shen, D.D., Artru, A.A. & Adkison, K.K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv. Drug Deliv. Rev. 56, 1825-1857 (2004).
66. Ball, K., Bouzom, F., Scherrmann, J.M., Walther, B. & Declèves, X. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. J. Pharm. Sci. 101, 4277-4292 (2012).
67. Gaohua, L., Neuhof, S., Jamei, M. & Rostami Hodjegan, A. A physiologically based pharmacokinetic (PBPK) brain model and its application in simulating drug disposition in brain. PAGE Meeting 2011, Athens, Greece, 7-10 June 2011; Abstr. 2078, 20 (2011).
68. Ohtsuki, S. et al. Simultaneous absolute protein quantifcation of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab. Dispos. 40, 83-92 (2012).
69. Bi, Y.A. et al. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab. Dispos. 40, 1085-1092 (2012).
70. Varma, M.V., Lai, Y., Feng, B., Litchfeld, J., Goosen, T.C. & Bergman, A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm. Res. 29, 2860-2873 (2012).
71. Yabe, Y., Galetin, A. & Houston, J.B. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab. Dispos. 39, 1808-1814 (2011).
72. Tachibana, T., Kato, M., Watanabe, T., Mitsui, T. & Sugiyama, Y. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica. 39, 430-443 (2009).
73. Klaassen, C.D. & Lu, H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci. 101, 186-196 (2008).
74. Gardiner, P. & Paine, S.W. The impact of hepatic uptake on the pharmacokinetics of organic anions. Drug Metab. Dispos. 39, 1930-1938 (2011).
75. Chow, E.C., Durk, M.R., Cummins, C.L. & Pang, K.S. 1Alpha, 25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efux of digoxin in mice in vivo. J. Pharmacol. Exp. Ther. 337, 846-859 (2011).